U.S. Markets closed

Curis, Inc. (CRIS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7920-0.0022 (-0.28%)
At close: 04:00PM EDT
0.8200 +0.03 (+3.54%)
After hours: 06:35PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7942
Bid0.7602 x 800
Ask0.8000 x 1100
Day's Range0.7500 - 0.8700
52 Week Range0.7500 - 15.6000
Avg. Volume2,420,961
Market Cap72.554M
Beta (5Y Monthly)2.88
PE Ratio (TTM)N/A
EPS (TTM)-0.4620
Earnings DateMar 14, 2022 - Mar 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.80
  • PR Newswire

    Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Association 2022 Hybrid Congress (EHA), which will be held virtually and in-person in Vienna on June 9-12, 2022. The abstracts include data from both the TakeAim Leukemia and TakeAim Lymphoma studies as well as other studies by Curis and independent col

  • Insider Monkey

    10 Stocks to Invest in Under $20 According to Michael Castor’s Sio Capital

    In this piece, we will take a look at the ten stocks to invest in under $20 according to Sio Capital. To skip the bottom five stocks in this list, head on over to 5 Stocks to Invest In Under $20 According to Michael Castor’s Sio Capital. Sio Capital is a hedge fund based out […]

  • Motley Fool

    Curis (CRIS) Q1 2022 Earnings Call Transcript

    At this time, I'd like to turn the conference call over to Curis' vice president of investor relations and corporate communications, Craig West. Thank you and welcome to Curis's first quarter 2022 earnings call. Joining me on today's call are Jim Dentzer, president and chief executive officer; Bill Steinkrauss, chief financial officer and chief administrative officer; Bob Martell, head of R&D. We will also be available for a question-and-answer period at the end of the call.